Abstract
Treatment of maternal chronic myeloid leukemia with imatinib mesylate is avoided because of potential fetal effects. Two women with progression of disease during pregnancy required imatinib therapy. Concentrations of imatinib in maternal blood, placenta, umbilical cord blood and breast milk were 886, 2452, 0 to 157, and 596 ng/ml, respectively. Concentrations of the active metabolite CGP74588 in maternal blood, placenta, umbilical cord blood and breast milk were 338, 1462, 0 and 1513 ng/ml, respectively. As Imatinib and CGP74588 cross the mature placenta poorly, use of the drug after the first trimester may be reasonable under some circumstances. Imatinib and CGP74588 are found in breast milk, and therefore avoidance of breastfeeding is advisable.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Copeland LJ, Landon MB . Malignant diseases and pregnancy In Gabbe S, Niebyl J, and Simpson J (eds). Obstetrics: Normal and Problem Pregnancies. Philadelphia (PA): Churchill Livingston, 2002; 1255–1281.
Savage DG, Antman KH . Imatinib Mesylate – a new oral targeted therapy. N Engl J Med 2002; 346: 683–693.
Investigators Brochure. STI571 (formerly CGP57148B) and data on file, Novartis Pharma AG, Basel, Switzerland..
Hensley ML, Ford JM . Imatinib Treatment: Specific Issues Related to Safety, Fertility, and Pregnancy. Seminars in Hematology 2003; 40: 21–25.
Ault P, Kantarjian H, O'Brien S, Faderl S, Beran M, Rios MB et al. Pregnancy among patients with cronic myeloid leukemia treated with imatinib. J Clin Oncol 2006; 24: 1204–1208.
Heartin E, Walkinshaw S, Clark RE . Successful outcome of pregnancy in chronic myeloid leukemia treated with imatinib. Leukemia Lymphoma 2004; 45: 1307–1308.
Alkindi S, Dennison D, Pathare A . Imatinib in pregnancy. Eur J Haematol 2005; 74: 535–537.
Ali R, Ozkalemkas F, Ozkocaman V, Ozcelik T, Ozan U, Kimya Y et al. Pregnancy under treatement of imatinib and successful labor in a patient with chronic myelogenous leukemia (CML): outcome of discontinuation of imatinib therapy after achieving a molecular remission. Leuk Res 2005; 29: 971–973.
Prabhash K, Sastry PS, Biswas G, Bakshi A, Prasad N, Menon H et al. Pregnancy outcome of two patients with imatinib. Ann Oncol 2005; 16: 1983–1984.
Choudhary DR, Mishra P, Kumar R, Mahapatra M, Choudhary VP . Pregnancy on imatinib: fatal outcome with meningocele. Ann Oncol 2006; 17: 178–179.
Parise RA, Ramanathan RK, Hayes MJ, Egorin MJ . Liquid chromatographic-mass spectrometric assay for quantitation of imatinib and its main metabolite (CGP 74588) in plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2003; 791: 39–44.
Bhatia R, Holtz M, Niu N, Gray R, Snyder DS, Sawyers CL et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 2003; 101: 4701–4707.
Peng B, Lloyd P, Schran H . Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 2005; 44: 879–894.
Cohen MH, Williams G, Johnson JR, Duan J, Gobburu J, Rahman A et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res 2002; 8: 935–942.
Druker BJ et al. Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia. NEJM 2001; 344: 1031–1037.
Widmer N, Colombo S, Buclin T, Decosterd L . Functional consequence of MDR1 expression on imatinib intracellular concentrations. Blood 2003; 102: 1142.
Mathias A, Hitti J, Unadkat J . P-glycoprotein and breast cancer resistance protein in human placentae of various gestational ages. Am J Physiol Regul Integr Comp Physiol 2005; 289: R963–R969.
Alvarez R, Kantarjian H, Cortes J . Biology of platelet-derived growth factor and its involvement in disease. Mayo Clin Proc 2006; 81: 1241–1257.
Nystrom H, Lindblom P, Wickman A, Andersson I et al. Platelet-derived growth factor B retention is essential for development of normal structure and function of conduit vessels and capillaries. Cardiovasc Res 2006; 71: 557–565.
Acknowledgements
We thank Dr Melanie Anne Egorin and Mr Atticus G Tarleton for assistance in obtaining the samples used for the analyses in this report.
Disclosure: Dr Merrill Egorin's laboratory is supported, in part, by a grant from Novartis Pharmaceutical Corporation.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Russell, M., Carpenter, M., Akhtar, M. et al. Imatinib mesylate and metabolite concentrations in maternal blood, umbilical cord blood, placenta and breast milk. J Perinatol 27, 241–243 (2007). https://doi.org/10.1038/sj.jp.7211665
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.jp.7211665
Keywords
This article is cited by
-
Chronic myeloid leukemia diagnosed in pregnancy: management and outcome of 87 patients reported to the European LeukemiaNet international registry
Leukemia (2024)
-
Guidelines for the treatment of chronic myeloid leukemia from the NCCN and ELN: differences and similarities
International Journal of Hematology (2023)
-
Family Planning and Pregnancy in Patients with Chronic Myeloid Leukemia
Current Hematologic Malignancy Reports (2023)
-
Fertility considerations in targeted biologic therapy with tyrosine kinase inhibitors: a review
Journal of Assisted Reproduction and Genetics (2021)
-
Successful pregnancy and delivery in a patient with chronic myeloid leukemia: a case report and review of the literature
SpringerPlus (2016)